Alterity Therapeutics Limited | PRAN

Alterity Therapeutics Limited traded at $0.66 this Friday July 1st, increasing $0.05 or 7.98 percent since the previous trading session. Looking back, over the last four weeks, Alterity Therapeutics Limited gained 8.65 percent. Over the last 12 months, its price fell by 62.29 percent. Looking ahead, we forecast Alterity Therapeutics Limited to be priced at 0.62 by the end of this quarter and at 0.57 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
0.66
Daily Change
7.98%
Yearly
-62.29%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
Insmed 20.91 1.19 6.03% -26.63%
Mirati Therapeutics 70.44 3.31 4.93% -57.97%
Alterity Therapeutics Limited 0.66 0.05 7.98% -62.29%

Indexes Price Day Year
USND 11114 93.17 0.84% -24.08%

Alterity Therapeutics Limited
Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company focuses on developing disease modifying treatments for neurodegenerative conditions. The Company's lead product candidate, ATH434, is being used for the treatment of various Parkinson's disease, Dementia with lewy bodies (DLB) as well as various forms of atypical Parkinsonism, such as Multiple System Atrophy (MSA). ATH434, is a set of molecules designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. The Company also has a drug discovery platform generating chemical to intercede in disease processes.